|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cohen HT and McGovern FJ: Renal-cell
carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Curti BD: Renal cell carcinoma. JAMA.
292:97–100. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ge YZ, Wu R, Xin H, Zhu M, Lu TZ, Liu H,
Xu Z, Yu P, Zhao YC, Li MH, et al: A tumor-specific microRNA
signature predicts survival in clear cell renal cell carcinoma. J
Cancer Res Clin Oncol. 141:1291–1299. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ishihara T, Seki N, Inoguchi S, Yoshino H,
Tatarano S, Yamada Y, Itesako T, Goto Y, Nishikawa R, Nakagawa M
and Enokida H: Expression of the tumor suppressive miRNA-23b/27b
cluster is a good prognostic marker in clear cell renal cell
carcinoma. J Urol. 192:1822–1830. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cummins JM and Velculescu VE: Implications
of micro-RNA profiling for cancer diagnosis. Oncogene.
25:6220–6227. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Alvarez-Garcia I and Miska E: MicroRNA
functions in animal development and human disease. Development.
132:4653–4662. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Luo M, Shen D, Wang W and Xian J: Aberrant
expression of microRNA-26b and its prognostic potential in human
cervical cancer. Int J Clin Exp Pathol. 8:5542–5548.
2015.PubMed/NCBI
|
|
9
|
Ha TY: MicroRNAs in human diseases: From
cancer to cardiovascular disease. Immune Netw. 11:135–154. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li M, Wang Y, Song Y, Bu R, Yin B, Fei X,
Guo Q and Wu B: MicroRNAs in renal cell carcinoma: A systematic
review of clinical implications (Review). Oncol Rep. 33:1571–1578.
2015.PubMed/NCBI
|
|
11
|
Calvo E, Schmidinger M, Heng DY, Grünwald
V and Escudier B: Improvement in survival end points of patients
with metastatic renal cell carcinoma through sequential targeted
therapy. Cancer Treat Rev. 50:109–117. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
O'Connell RM, Taganov KD, Boldin MP, Cheng
G and Baltimore D: MicroRNA-155 is induced during the macrophage
inflammatory response. Proc Natl Acad Sci USA. 104:1604–1609. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rodriguez A, Vigorito E, Clare S, Warren
MV, Couttet P, Soond DR, van Dongen S, Grocock RJ, Das PP, Miska
EA, et al: Requirement of bic/microRNA-155 for normal immune
function. Science. 316:608–611. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thai TH, Calado DP, Casola S, Ansel KM,
Xiao C, Xue Y, Murphy A, Frendewey D, Valenzuela D, Kutok JL, et
al: Regulation of the germinal center response by microRNA-155.
Science. 316:604–608. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tili E, Croce CM and Michaille JJ:
miR-155: On the crosstalk between inflammation and cancer. Int Rev
Immunol. 28:264–284. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Juan D, Alexe G, Antes T, Liu H,
Madabhushi A, Delisi C, Ganesan S, Bhanot G and Liou LS:
Identification of a microRNA panel for clear-cell kidney cancer.
Urology. 75:835–841. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen CZ: MicroRNAs as oncogenes and tumor
suppressors. N Engl J Med. 353:1768–1771. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kumar MS, Lu J, Mercer KL, Golub TR and
Jacks T: Impaired microRNA processing enhances cellular
transformation and tumorigenesis. Nat Genet. 39:673–677. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hale JS, Nelson LT, Simmons KB and Fink
PJ: Bcl-2-interacting mediator of cell death influences
autoantigen-driven deletion and TCR revision. J Immunol.
186:799–806. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bouamar H, Jiang D, Wang L, Lin AP, Ortega
M and Aguiar RC: MicroRNA 155 control of p53 activity is context
dependent and mediated by Aicda and Socs1. Mol Cell Biol.
35:1329–1340. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Amente S, Zhang J, Lavadera ML, Lania L,
Avvedimento EV and Majello B: Myc and PI3K/AKT signaling
cooperatively repress FOXO3a-dependent PUMA and GADD45a gene
expression. Nucleic Acids Res. 39:9498–9507. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cai ZK, Chen Q, Chen YB, Gu M, Zheng DC,
Zhou J and Wang Z: microRNA-155 promotes the proliferation of
prostate cancer cells by targeting annexin 7. Mol Med Rep.
11:533–538. 2015.PubMed/NCBI
|
|
24
|
Lao G, Liu P, Wu Q, Zhang W, Liu Y, Yang L
and Ma C: Mir-155 promotes cervical cancer cell proliferation
through suppression of its target gene LKB1. Tumour Biol.
35:11933–11938. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Novara G, Ficarra V, Antonelli A, Artibani
W, Bertini R, Carini M, Cosciani Cunico S, Imbimbo C, Longo N,
Martignoni G, et al: Validation of the 2009 TNM version in a large
multi-institutional cohort of patients treated for renal cell
carcinoma: Are further improvements needed? Eur Urol. 58:588–595.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dinami R, Ercolani C, Petti E, Piazza S,
Ciani Y, Sestito R, Sacconi A, Biagioni F, le Sage C, Agami R, et
al: miR-155 drives telomere fragility in human breast cancer by
targeting TRF1. Cancer Res. 74:4145–4156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li T, Yang J, Lv X, Liu K, Gao C, Xing Y
and Xi T: miR-155 regulates the proliferation and cell cycle of
colorectal carcinoma cells by targeting E2F2. Biotechnol Lett.
36:1743–1752. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kong W, He L, Coppola M, Guo J, Esposito
NN, Coppola D and Cheng JQ: MicroRNA-155 regulates cell survival,
growth and chemosensitivity by targeting FOXO3a in breast cancer. J
Biol Chem. 285:17869–12879. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Spinetti G, Cordella D, Fortunato O,
Sangalli E, Losa S, Gotti A, Carnelli F, Rosa F, Riboldi S, Sessa
F, et al: Global remodeling of the vascular stem cell niche in bone
marrow of diabetic patients: Implication of the microRNA-155/FOXO3a
signaling pathway. Circ Res. 112:510–522. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Anderson MJ, Viars CS, Czekay S, Cavenee
WK and Arden KC: Cloning and characterization of three human
forkhead genes that comprise an FKHR-like gene subfamily. Genomics.
47:187–199. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tran H, Brunet A, Grenier JM, Datta SR,
Fornace AJ Jr, DiStefano PS, Chiang LW and Greenberg ME: DNA repair
pathway stimulated by the forkhead transcription factor FOXO3a
through the Gadd45 protein. Science. 296:530–534. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sunters A, de Fernández Mattos S, Stahl M,
Brosens JJ, Zoumpoulidou G, Saunders CA, Coffer PJ, Medema RH,
Coombes RC and Lam EW: FoxO3a transcriptional regulation of Bim
controls apoptosis in paclitaxel-treated breast cancer cell lines.
J Biol Chem. 278:49795–49805. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ni D, Ma X, Li HZ, Gao Y, Li XT, Zhang Y,
Ai Q, Zhang P, Song EL, Huang QB, et al: Downregulation of FOXO3a
promotes tumor metastasis and is associated with metastasis-free
survival of patients with clear cell renal cell carcinoma. Clin
Cancer Res. 20:1779–1790. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ling N, Gu J, Lei Z, Li M, Zhao J, Zhang
HT and Li X: microRNA-155 regulates cell proliferation and invasion
by targeting FOXO3a in glioma. Oncol Rep. 30:2111–2118.
2013.PubMed/NCBI
|
